Cymax Mouse IL-6 ELISA Kit
- Known as:
- Cymax Mouse Interleukin-6 Enzyme-linked immunosorbent assay test Kit
- Catalog number:
- lf-ek0270
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- Abfrontier
- Gene target:
- Cymax Mouse IL-6 ELISA Kit
Related genes to: Cymax Mouse IL-6 ELISA Kit
- Gene:
- CEBPB NIH gene
- Name:
- CCAAT enhancer binding protein beta
- Previous symbol:
- TCF5
- Synonyms:
- LAP, CRP2, NFIL6, IL6DBP, C/EBP-beta
- Chromosome:
- 20q13.13
- Locus Type:
- gene with protein product
- Date approved:
- 1991-02-27
- Date modifiied:
- 2018-02-23
- Gene:
- CEBPD NIH gene
- Name:
- CCAAT enhancer binding protein delta
- Previous symbol:
- -
- Synonyms:
- CRP3, CELF, C/EBP-delta, NF-IL6-beta
- Chromosome:
- 8q11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1992-06-24
- Date modifiied:
- 2018-02-23
- Gene:
- ENTPD6 NIH gene
- Name:
- ectonucleoside triphosphate diphosphohydrolase 6
- Previous symbol:
- CD39L2, IL6ST2
- Synonyms:
- NTPDase-6, dJ738P15.3
- Chromosome:
- 20p11.21
- Locus Type:
- gene with protein product
- Date approved:
- 1998-03-20
- Date modifiied:
- 2019-02-28
- Gene:
- IL6 NIH gene
- Name:
- interleukin 6
- Previous symbol:
- IFNB2
- Synonyms:
- IL-6, BSF2, HGF, HSF
- Chromosome:
- 7p15.3
- Locus Type:
- gene with protein product
- Date approved:
- 1986-01-01
- Date modifiied:
- 2017-07-12
- Gene:
- IL6RP1 NIH gene
- Name:
- interleukin 6 receptor pseudogene 1
- Previous symbol:
- IL6RL1
- Synonyms:
- -
- Chromosome:
- 9q22.2
- Locus Type:
- pseudogene
- Date approved:
- 1991-08-18
- Date modifiied:
- 2014-11-19
Related products to: Cymax Mouse IL-6 ELISA Kit
Related articles to: Cymax Mouse IL-6 ELISA Kit
- Hypertension is highly prevalent among patients with chronic kidney disease (CKD), where it functions both as a cause and a consequence of disease progression. Renin-angiotensin-aldosterone system inhibitors remain foundational for nephroprotection, with calcium channel blockers, thiazide diuretics and mineralocorticoid receptor antagonists (MRAs) commonly added to improve blood pressure (BP) control. However, the limited efficacy of thiazides at low estimated glomerular filtration rate and the increased risk of hyperkalemia with MRAs, together with polypharmacy, and suboptimal adherence, further complicate BP management in advanced CKD. Emerging pharmacologic strategies - including nonsteroidal MRAs, aldosterone synthase inhibitors, and RNA-based therapies - offer mechanism-oriented approaches to optimize cardiorenal outcomes. Complementary interventional strategies, such as renal denervation and low-intensity shockwave intravascular lithotripsy, are being evaluated for their potential to improve BP control, while therapies targeting inflammatory pathways, enhancing natriuretic peptide signaling, or leveraging vaccine-based mechanisms may address residual risk and adherence challenges. In this review, we provide a comprehensive overview of emerging pharmacologic and interventional approaches for BP management in nondialysis CKD, highlighting mechanism-driven innovations and their potential clinical translation. - Source: PubMed
Publication date: 2026/09/18
Damianaki AikateriniIliakis PanagiotisVakka AngelikiStambolliu EmelinaSakalidis AthanasiosDimitriadis KyriakosPetras DimitriosTsioufis Konstantinos - Streptococcus pneumoniae is a major cause of bacteremia and sepsis, and rising antimicrobial resistance necessitates new therapies. This study aimed to screen ginsenosides with antipneumococcal activity and to evaluate antibacterial effects of candidate compound. Among nine ginsenosides tested in vitro, only Ginsenoside C-K exhibited significant antibacterial activity with a minimum inhibitory concentration (MIC) of 4-8 µg·mL-1. Further investigation demonstrated that Ginsenoside C-K exerted rapid bactericidal effects and effectively inhibited both the formation and stability of biofilms. In addition, it disrupted bacterial membrane integrity and induced the accumulation of reactive oxygen species (ROS). Moreover, Ginsenoside C-K treatment of S. pneumoniae-infected cells was associated with the restoration of mitochondrial membrane potential and reduced expression of pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β. In vivo, treatment with Ginsenoside C-K significantly improved the survival rate of infected hosts to 60%-70%. In summary, Ginsenoside C-K exhibits potent antimicrobial activity both in vitro and in vivo, combining antibacterial, antibiofilm, and antiinflammatory effects. This study provides new experimental evidence supporting the application of ginsenoside-derived natural products in the treatment of pneumococcal infections and offers valuable insight for the development of novel antimicrobial lead compounds. - Source: PubMed
Publication date: 2026/09/23
Wang HaiboXu LifangSheng XuehuiYu LiqiangWang QianqianSong XianbinZhu Jiangang - The application of tourniquets during limb surgery can lead to ischemia-reperfusion (IR) injury, a pathological process characterized by excessive oxidative stress, increased inflammatory signaling, and progressive muscle fiber damage. Hesperidin, a bioactive flavonoid derived from citrus fruits, is known for its antioxidant and anti-inflammatory properties. This study evaluated the protective effects of hesperidin against lower-limb skeletal muscle IR injury and investigated the molecular pathways potentially associated with these effects. Male Wistar rats were allocated to four groups: control, hesperidin alone, IR (2 h of ischemia followed by 2 h of reperfusion), and IR + hesperidin (100 mg/kg administered 30 min before ischemia). Histological examination of the gastrocnemius muscle was performed, and plasma markers of muscle injury, including creatine kinase (CK), lactate dehydrogenase (LDH), and alkaline phosphatase (ALP), were measured. Oxidative stress and antioxidant parameters (MDA, SOD, CAT, and GPx), components of the Nrf2/HO-1/NQO1 pathway, inflammatory mediators (NF-κB, TNF-α, IL-6, and IL-1β), pyroptosis-associated markers (NLRP3 and caspase-1), and apoptosis-associated proteins (Bax and caspase-3) were also assessed. IR resulted in pronounced muscle fiber disruption, elevated plasma injury markers, increased lipid peroxidation, and reduced antioxidant capacity. IR also decreased Nrf2, HO-1, and NQO1 levels while increasing NF-κB, NLRP3, caspase-1, pro-inflammatory cytokines, and apoptosis-associated proteins. Hesperidin pretreatment markedly attenuated these changes by preserving muscle structural integrity, reducing plasma injury markers and lipid peroxidation, restoring antioxidant enzyme activity, increasing Nrf2/HO-1/NQO1-associated antioxidant responses, and reducing NF-κB-associated inflammatory, NLRP3/caspase-1-associated pyroptotic, and apoptotic responses. Overall, hesperidin pretreatment protected skeletal muscle against tourniquet-induced IR injury and was associated with enhanced Nrf2-mediated antioxidant defenses and attenuation of NF-κB-associated inflammation and NLRP3/caspase-1-associated responses. These findings support further investigation of hesperidin as a potential prophylactic intervention for reducing tourniquet-associated lower-limb IR injury. - Source: PubMed
Publication date: 2026/09/22
Albarakati Alaa Jameel A - Thymic involution, the age-related replacement of thymic soft tissue by fat, has been linked to immunosenescence and chronic inflammation, processes implicated in aging-associated comorbidities. Untreated HIV infection is associated with thymic atrophy and reduced thymic output. Although thymic function may normalize after initiation of antiretroviral therapy, the long-term consequences of HIV infection on thymic involution in people with HIV (PWH) remain unknown. We investigated whether thymic involution differs between PWH and population controls, and how its association with markers of T-cell differentiation and inflammation in PWH. We conducted a cross-sectional analysis including 654 PWH aged ≥ 40 years from the Copenhagen Comorbidity in HIV Infection study and 637 age- and sex-matched population controls from the Copenhagen General Population Study. Thymic tissue was graded on a 4-point scale based on adipose-to-soft tissue proportion on chest CT scans, with higher grades reflecting more soft tissue (i.e., less involution). Thymic output was assessed by signal joint T-cell receptor excision circle (sjTREC) content in buffy coats. PWH had higher odds of a higher thymus grade compared to population controls (adjusted-OR = 1.75, 95% CI = 1.31-2.33), after adjustment for age, sex, pack-years, BMI, waist-to-hip ratio, physical activity, and alcohol intake. Higher thymus grade was associated with greater sjTREC content, and among PWH with higher proportions of naïve CD4 and CD8 T cells, lower proportions of senescent T cells, and lower IL-6 and hs-CRP levels. Our findings indicate thymic involution may be attenuated in some PWH on long-term treatment, and that the preserved thymic output may help mitigate chronic inflammation. - Source: PubMed
Vanbellinghen Manon CBoyd AndersJohansen Andreas OhrtSuarez-Zdunek Moises AlbertoKnudsen Andreas DehlbækKristensen Thomas SkårupKühl Jørgen TobiasSigvardsen Per EjlstrupPham Michael Huy CuongLarsen Andreas FuchsKofoed Klaus FuglsangNordestgaard Børge GrønneAfzal ShoaibKootstra NeeltjeNielsen Susanne DamReiss Peter - Idiopathic multicentric Castleman disease (iMCD) is a potentially fatal immunologic disorder marked by widespread lymphadenopathy and inflammation. Siltuximab, an interleukin-6 (IL-6) inhibitor, is the only FDA-approved treatment for adult patients with iMCD. Limited data exist on pediatric iMCD or its responsiveness to siltuximab. We hypothesize that pediatric iMCD patients will present and respond similarly to adult patients. - Source: PubMed
Publication date: 2026/09/23
Austin BridgetPierson Sheila KDacus Kelley CBustamante Mateo SarmientoShyamsundar SaishravanBorys LarissaMcHugh KaylaIrvine AbiolaJo YoojinBagg AdamLechowicz Mary JoAlapat DaisyChadburn AmyLim Megan SSrkalovic Gordanvan Rhee FritsFajgenbaum David CBrandstadter Joshua D